Antibodies directed against amyloid-beta peptide and methods using same
AssigneeRinat Neuroscience Corp.
InventorsArnon ROSENTHAL, Jaume PONS, Wei-Hsien HO
Life of this patent
Estimating the term…
Abstract
Antibodies directed to the C-terminal side of β-amyloid peptide and methods of using these antibodies for diagnosing and treatment of Alzheimer's disease and Aβ peptide associated diseases are described.
Claims14
A monoclonal antibody that specifically binds to a β-amyloid peptide or an aggregated form of a β-amyloid peptide, wherein the said antibody binds to an epitope on Aβ1-40 that includes amino acids 25-34 and 40, wherein said antibody binds to Aβ1-40 with higher affinity than its binding to Aβ1-42 and Aβ1-43, wherein said antibody binds to Aβ22-37 with a KD of less than 1 μM.
A method for treating a disease associated with aberrant deposition of β-amyloid in a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to a β-amyloid peptide or an aggregated form of a β-amyloid peptide, wherein the said antibody binds to an epitope on Aβ1-40 that includes amino acids 25-34 and 40, wherein said antibody binds to Aβ1-40 with higher affinity than its binding to Aβ1-42 and Aβ1-43, wherein said antibody binds to Aβ22-37 with a KD of less than 1 μM.
Dependencies are inferred from the claim text.